AS Tallinna Vesi’s sales revenues for the first half of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AS Tallinna Vesi’s sales revenues for the first half of 2016 increased by 5.7% year-on-year

The Company’s sales revenues for the first half of 2016 were EUR 28.87 million, being 5.7% or EUR 1.56 million higher than in the same period of 2015. The sales increase was mostly down to higher revenues from water and wastewater services and construction and asphalting services.

At the same time, the operating profit for the first 6 months of 2016, was EUR 12.47 million and net profit EUR 10.91 million. Compared to the same period in 2015, the operating profit declined by 3.4% or EUR 0,45 million and net profit by 24.8% or EUR 2.11 million.

Decrease in operating profit was mostly induced by higher legal costs. The decline in the fair value of SWAP contracts of EUR 0.87 million, compared to the EUR 1.41 million positive change in the same period in 2015, had an impact on the net profit. At the same time, the interest costs for the first half of 2016 were EUR 0.65 million lower than in the first half of 2015. Consequently, the net profit for the first six months in 2016, without the effect of the change in the fair value of swap contracts, was EUR 7.3 million and EUR 7.2 million for 2015.

AS Tallinna Vesi is involved in two court proceedings in connection with the Services Agreement and the tariffs, both locally and internationally. During the first half of 2016, no hearings were held. The timetable of the international Arbitration Proceedings is public and can be found on the ICSID website, a link to which is included on the investors website as part of the 22 nd June 2015 announcement ( please see here ). The final hearing is scheduled for November 2016.

         Mariliis Mia Topp          AS Tallinna Vesi          Head of Communications          Ph: (+372) 62 62 275          mariliismia.topp@tvesi.ee

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

OnTime's Bold Vision: Transforming Home Healthcare Admin

Updated Category News Views 7

Changing the Game for Home Healthcare Every now and then, an idea rolls in that speaks to a real need, and OnTime's push to soften the burdens of the home healthcare industry might just be one of those. Built from grassroots experience, they're dropping efforts to modernize the back-end monotony so healthcare workers can zero in on, well, healthcare. A Nose-Dive into...

Continue Reading
Image Analysis Group Unveils DYNAMIKA V.7 for Clinical Trials

Updated Category News Views 185

Introduction to DYNAMIKA V.7 by Image Analysis Group Image Analysis Group (IAG) has recently launched DYNAMIKA V.7, an advanced cloud platform tailored for clinical trial imaging. Following stringent audits and certifications, including SOC II Type I compliance and British Standards Institute (BSI) surveillance audit certification, this platform stands out in its field....

Continue Reading
Sanofi's Strategic Move to Enhance Adult Vaccination Pipeline

Updated Category News Views 95

Sanofi Strengthens Its Vaccination Portfolio Sanofi SA (NASDAQ: SNY) has made a significant step in the healthcare sector by acquiring Dynavax Technologies Corporation (NASDAQ: DVAX) for approximately $2.2 billion. This acquisition, which involves a cash purchase price of $15.50 per share, signals Sanofi's commitment to enhancing its capabilities in the adult immunization...

Continue Reading
Miral Impact Fund: A New Era for Community and Environment

Updated Category News Views 135

Introducing the Miral Impact Fund Miral has taken a significant step towards environmental stewardship and social responsibility by launching the Miral Impact Fund. This initiative, launched in partnership with the Authority of Social Contribution – Ma'an, aims to create a positive impact within communities by addressing pressing social issues while promoting...

Continue Reading
Class Action Update for Regeneron Pharmaceuticals Investors

Updated Category News Views 125

Class Action Lawsuit Overview for Regeneron Pharmaceuticals Levi & Korsinsky, LLP has announced that Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) investors should take note of a pending class action lawsuit concerning alleged securities fraud. Understanding the Class Action The lawsuit aims to recover losses for investors adversely affected by claims of fraud that...

Continue Reading